Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver spread
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of lenvatinib (a targeted therapy) plus standard chemotherapy for pancreatic neuroendocrine tumors that have spread to the liveraging after first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic neuroendocrine tumor (a rare type of pancreatic cancer) that has spread to your liver.
- Your cancer has progressed or you couldn't tolerate your first treatment, and you are now eligible for a second line of therapy.
- You have at least one measurable tumor that can be tracked by imaging.
- You can manage your daily activities (ECOG performance status 0 or 1).
- You have adequate organ function (blood counts, liver and kidney function) and at least 12 weeks of life expectancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
Hear when a new Pancreatic Neuroendocrine Tumor With Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.